Kazia Therapeutics (KZIA) Receivables - Net (2009 - 2025)
Kazia Therapeutics' (KZIA) quarterly Receivables - Net came in at $233438.2 in Q4 2025, up 271.33% YoY from $62866.2 in Q4 2024, and up 272.28% on a QoQ basis from $62705.5 in Q2 2025.
Kazia Therapeutics (KZIA) Receivables - Net (2009 - 2025) Analysis & Trends
Kazia Therapeutics (KZIA) has 17 years of Receivables - Net data on file, last reported at $233438.2 in Q4 2025.
- Quarterly Receivables - Net rose 271.33% year-over-year to $233438.2 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $233438.2 (up 271.33% YoY) and the FY2025 annual result came in at $88322.8, down 96.56% from the prior year.
- Receivables - Net rose to $233438.2 in Q4 2025, from $62705.5 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $2.6 million in Q2 2023 to a low of $55154.8 in Q4 2021.
- A 5-year average of $1.1 million and a median of $149309.3 in 2022 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2022 — Receivables - Net soared 4325.72% — and 2025, when it plunged 97.56%.
- Tracing KZIA's Receivables - Net over 5 years: stood at $55154.8 in 2021, then surged by 4325.72% to $2.4 million in 2022, then declined by 0.19% to $2.4 million in 2023, then slumped by 97.42% to $62866.2 in 2024, then jumped by 271.33% to $233438.2 in 2025.
- The last three Receivables - Net figures came in at $233438.2 (Q4 2025), $62705.5 (Q2 2025), and $62866.2 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kazia Therapeutics | 4.22 Bn | 4.22 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 233,438.21 |
| Dec 31, 2025 | 233,438.21 |
| Jun 30, 2025 | 62,705.46 |
| Jun 30, 2025 | 62,705.46 |
| Dec 31, 2024 | 62,866.16 |
| Dec 31, 2024 | 62,866.16 |
| Jun 30, 2024 | 2.57 Mn |
| Jun 30, 2024 | 2.57 Mn |
| Dec 31, 2023 | 2.44 Mn |
| Dec 31, 2023 | 2.44 Mn |
| Jun 30, 2023 | 2.61 Mn |
| Jun 30, 2023 | 2.61 Mn |
| Dec 31, 2022 | 2.44 Mn |
| Dec 31, 2022 | 2.44 Mn |
| Jun 30, 2022 | 65,180.42 |
| Jun 30, 2022 | 65,180.42 |
| Dec 31, 2021 | 55,154.79 |
| Dec 31, 2021 | 55,154.79 |
| Jun 30, 2021 | 64,684.63 |
| Jun 30, 2021 | 64,684.63 |